FMS Stock Recent News

Fresenius Medical Care AG (NYSE:FMS ) Q2 2024 Earnings Call July 30, 2024 8:00 AM ET Company Participants Dominik Heger - Head, Investor Relations Helen Giza - Chief Executive Officer and Chair Martin Fischer - Chief Financial Officer Conference Call Participants Veronika Dubajova - Citi Richard Felton - Goldman Sachs Graham Doyle - UBS Hassan Al-Wakeel - Barclays Victoria Lambert - Berenberg Hugo Solvet - BNP Paribas James Vane-Tempest - Jefferies David Adlington - JPMorgan Falko Friedrichs - Deutsche Bank Robert Davies - Morgan Stanley Marianne Bulot - Bank of America Dominik Heger Thank you, Alice. Good morning, good afternoon or good evening, depending on where you are.

Organic revenue growth of +2.3% supported by both segments Care Delivery and Care Enablement Operating income1 and operating income margin1 increase driven by Care Enablement Additional FME25 savings of EUR 57 million achieved and on track to reach the upper end of the full year savings target range Further divestitures closed as execution of portfolio optimization program continues Net financial debt and net leverage ratio further improved FY 2024 outlook confirmed BAD HOMBURG, Germany , July 30, 2024 /PRNewswire/ -- "In the second quarter, we further improved our financial performance while executing against our strategic plan and the company transformation. This quarter is another important proof point for the operational turnaround as we remain focused to deliver on our targets", said Helen Giza, Chief Executive Officer of Fresenius Medical Care AG.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Fresenius Medical (FMS) continues to gain traction through its broad dialysis product and service portfolio. Intense competition is a woe.

BELGRADE, Mont., July 01, 2024 (GLOBE NEWSWIRE) -- Bridger Aerospace Group Holdings, Inc. (“Bridger”, “the Company” or “Bridger Aerospace”), (NASDAQ: BAER, BAERW), one of the nation's largest aerial firefighting companies, today announced that it has acquired FMS Aerospace (“FMS”). FMS, based in Huntsville, Alabama, is a turn-key provider of airframe modification and integration solutions for government and commercial customers including instrumentation, flight testing and airworthiness certification. The consideration for the transaction was $17.51 million in equity, with an additional contingent equity earn-out consideration of up to $3.09 million.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Fresenius Medical Care enters virtual power purchase agreements for renewable energy to clearly step forward in reducing CO2 emissions footprint Company enacts five virtual power purchase agreements for around 580 gigawatt hours per year with wind and solar farms in Germany and the U.S. Energy farms scheduled to go into operation in 2024 and 2025 Important milestone for strategic sustainability goal to achieve climate-neutrality by 2040 BAD HOMBURG, Germany , June 12, 2024 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for people with kidney disease, has signed five virtual power purchase agreements (vPPAs) with wind and solar energy project developers in Germany and the U.S. The projects are expected to feed around 580 gigawatt hours of renewable energy into the grid, which equals up to 46 percent of FME's most recently reported global consumption. The company is thus taking an important step towards its goal of reducing emissions i

Fresenius Medical (FMS) continues to gain traction through its broad dialysis product and service portfolio. Intense competition is a woe.

The change of the rating outlook reflects the company's progress in restoring credit metrics and the commitment to maintain its investment grade rating FME is expected to maintain its good growth momentum, while continuing to improve operational performance on the back of its strong transformation progress Solid deleveraging prospects BAD HOMBURG, Germany , May 23, 2024 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, today received from S&P Global, a leading rating agency, the change of its rating outlook to stable from negative (bbb-, stable outlook). Moody's changed the credit rating outlook from negative to stable on May 17 (baa3, stable outlook).

Enhancing kidney care through innovative approaches by data-driven insights and real-world evidence Company-wide experts highlight robust anonymized dialysis database CONVINCE study and the remarkable decrease of 23% in mortality rates for patients treated with high-volume hemodiafiltration will be presented BAD HOMBURG, Germany , May 21, 2024 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, today announced the presentation of nearly 40 company-affiliated research abstracts at the 61st European Renal Association (ERA) Congress, taking place May 23-26, 2024, in Stockholm, Sweden and virtually. "Our mission to improve the lives of people living with kidney disease requires working continually to enhance the standard of kidney disease care, and research plays an important role in that advancement," said Dr. Frank Maddux, Global Chief Medical Officer and Member of the Management Board for Fresenius M